Statements (61)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:Company
|
gptkbp:bfsLayer |
5
|
gptkbp:bfsParent |
gptkb:Aduro_Biotech,_Inc.
|
gptkbp:clinical_trial |
Phase 1 trials
Phase 2 trials |
gptkbp:collaborated_with |
research institutions
biotech firms |
gptkbp:collaborates_with |
academic institutions
|
gptkbp:collaborations |
universities
clinical centers |
gptkbp:community_engagement |
gptkb:hospital
patient advocacy groups |
gptkbp:develops |
cancer treatments
|
gptkbp:employs |
gptkb:physicist
|
gptkbp:focuses_on |
gptkb:vaccine
gptkb:drug personalized medicine cancer immunotherapy novel therapies |
gptkbp:founded |
gptkb:2014
|
gptkbp:has_mission |
improve cancer treatment
|
gptkbp:has_product |
ADU-741
ADU-CL-24 |
gptkbp:has_property |
patents
trademarks |
gptkbp:has_website |
adurobiotech.com
|
gptkbp:headquarters |
gptkb:Sweden
|
https://www.w3.org/2000/01/rdf-schema#label |
Aduro Biotech Sweden
|
gptkbp:is_active_in |
European market
global market |
gptkbp:is_engaged_in |
public-private partnerships
clinical development |
gptkbp:is_involved_in |
clinical trials
biomedical research therapeutic development research collaborations |
gptkbp:is_known_for |
innovative therapies
patient-centric approach |
gptkbp:is_part_of |
biopharmaceutical industry
|
gptkbp:is_recognized_by |
industry awards
research publications |
gptkbp:is_supported_by |
gptkb:Company
grants government funding philanthropic donations |
gptkbp:leadership |
gptkb:CEO
scientific advisory board |
gptkbp:located_in |
gptkb:Lund
|
gptkbp:part_of |
Aduro Biotech Inc.
|
gptkbp:participates_in |
clinical research
|
gptkbp:partnerships |
pharmaceutical companies
|
gptkbp:receives_funding_from |
gptkb:Company
|
gptkbp:regulatory_compliance |
gptkb:FDA
gptkb:EMA |
gptkbp:research_focus |
T-cell activation
immune response |
gptkbp:strategic_importance |
enhance research capabilities
expand product pipeline |
gptkbp:technology |
genetic engineering
biologics |
gptkbp:vision |
transform cancer care
|